Karyopharm Therapeutics Inc.KPTINASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank86
Studio
Year-over-Year Change

EBITDA as a percentage of revenue

Latest
-53.84%
↑ 99% vs avg
Percentile
P86
Within normal range
Streak
1 yr
Consecutive declineContracting
Average
-8006.25%
Historical baseline
PeriodValueYoY Change
TTM-53.84%-102.6%
2024-26.58%+67.2%
2023-81.09%+8.6%
2022-88.69%-91.9%
2021-46.22%+70.2%
2020-155.30%+65.3%
2019-447.34%+22.5%
2018-577.38%+92.8%
2017-7988.04%+88.7%
2016-70598.05%-